AbbVie Inc.’s stock rose 5% early Friday to lead S&P 500 gainers premarket, after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology ...

AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term ...

Quarterly sales of Humira declined 49% to $1.68 billion, a steeper fall than the $1.99 billion analysts expected, according to data compiled by LSEG. Once the world's best-selling drug ...

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.

Humira is the company's blockbuster immunology drug, which has faced competition from biosimilars since 2023. North Chicago, Ill.-based AbbVie (ABBV) had a loss per share of 2 cents, due to an ...

AbbVie is a Dividend King that's quickly moving past reliance on Humira. Enbridge shouldn't be affected by potential Canadian ...

(Reuters) -AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship ...

AbbVie made a change atop its board of directors, naming CEO Robert Michael as chairman on Friday morning. The pharma giant announced that Michael will succeed Richard A. Gonzalez, the former CEO of ...